

Research article

Open Access

Lymphatic vessel density and function in experimental bladder cancer

Marcia R Saban*¹, Rheal Towner², Nataliya Smith², Andrew Abbott², Michal Neeman³, Carole A Davis¹, Cindy Simpson¹, Julie Maier⁴, Sylvie Mémet⁵, Xue-Ru Wu⁶ and Ricardo Saban¹

Address: ¹Department of Physiology, College of Medicine, Oklahoma University Health Sciences Center (OUHSC), Oklahoma City, OK 73104, USA, ²Small Animal MRI Core Facility, Free Radical Biology & Aging, Oklahoma Medical Research Foundation (OMRF), Oklahoma City, OK 73104, USA, ³Department of Biological Regulation, Weizmann Institute of Science, Rehovot, 76100, Israel, ⁴Oklahoma Medical Research Foundation (OMRF), Imaging Core Facility, Oklahoma City, Oklahoma 73104, USA, ⁵Unité de Mycologie Moléculaire, URA CNRS 3012, Institut Pasteur, 75724 Paris Cedex 15, France and ⁶Department of Urology, New York University Medical School, New York, NY 10016, USA

Email: Marcia R Saban* - marcia-saban@ouhsc.edu; Rheal Towner - rheal-towner@omrf.ouhsc.edu; Nataliya Smith - Nataliya-Smith@omrf.ouhsc.edu; Andrew Abbott - andrew-abbott@omrf.ouhsc.edu; Michal Neeman - michal.neeman@weizmann.ac.il; Carole A Davis - carole-davis@ouhsc.edu; Cindy Simpson - cindy-simpson@ouhsc.edu; Julie Maier - maierj@omrf.ouhsc.edu; Sylvie Mémet - symemet@pasteur.fr; Xue-Ru Wu - wux01@med.nyu.edu; Ricardo Saban - ricardo-saban@ouhsc.edu

* Corresponding author

Published: 29 November 2007

Received: 28 September 2007

BMC Cancer 2007, 7:219 doi:10.1186/1471-2407-7-219

Accepted: 29 November 2007

This article is available from: <http://www.biomedcentral.com/1471-2407/7/219>

© 2007 Saban et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: The lymphatics form a second circulatory system that drains the extracellular fluid and proteins from the tumor microenvironment, and provides an exclusive environment in which immune cells interact and respond to foreign antigen. Both cancer and inflammation are known to induce lymphangiogenesis. However, little is known about bladder lymphatic vessels and their involvement in cancer formation and progression.

Methods: A double transgenic mouse model was generated by crossing a bladder cancer-induced transgenic, in which SV40 large T antigen was under the control of uroplakin II promoter, with another transgenic mouse harboring a *lacZ* reporter gene under the control of an NF- κ B-responsive promoter (κ B-*lacZ*) exhibiting constitutive activity of β -galactosidase in lymphatic endothelial cells. In this new mouse model (SV40-*lacZ*), we examined the lymphatic vessel density (LVD) and function (LVF) during bladder cancer progression. LVD was performed in bladder whole mounts and cross-sections by fluorescent immunohistochemistry (IHC) using LYVE-1 antibody. LVF was assessed by real-time *in vivo* imaging techniques using a contrast agent (biotin-BSA-Gd-DTPA-Cy5.5; Gd-Cy5.5) suitable for both magnetic resonance imaging (MRI) and near infrared fluorescence (NIRF). In addition, IHC of Cy5.5 was used for time-course analysis of co-localization of Gd-Cy5.5 with LYVE-1-positive lymphatics and CD31-positive blood vessels.

Results: SV40-*lacZ* mice develop bladder cancer and permitted visualization of lymphatics. A significant increase in LVD was found concomitantly with bladder cancer progression. Double labeling of the bladder cross-sections with LYVE-1 and Ki-67 antibodies indicated cancer-induced lymphangiogenesis. MRI detected mouse bladder cancer, as early as 4 months, and permitted to follow tumor sizes during cancer progression. Using Gd-Cy5.5 as a contrast agent for MRI-guided lymphangiography, we determined a possible reduction of lymphatic flow within the tumoral area.

In addition, NIRF studies of Gd-Cy5.5 confirmed its temporal distribution between CD31-positive blood vessels and LYVE-1 positive lymphatic vessels.

Conclusion: SV40-*lacZ* mice permit the visualization of lymphatics during bladder cancer progression. Gd-Cy5.5, as a double contrast agent for NIRF and MRI, permits to quantify delivery, transport rates, and volumes of macromolecular fluid flow through the interstitial-lymphatic continuum. Our results open the path for the study of lymphatic activity *in vivo* and in real time, and support the role of lymphangiogenesis during bladder cancer progression.

Background

De novo lymphangiogenesis influences different pathological courses via modulating tissue fluid homeostasis, macromolecule absorption, and leukocyte transmigration [1]. In addition, lymphatic vessels play a crucial role in a variety of human cancers [2]. Invasion of lymphatic vessels by tumor cells and subsequent development of lymph node metastases significantly influences the prognosis of cancer patients and, therefore, represents an integral part of tumor staging. Increasing knowledge of the tumor's biological significance in lymphatics within the tumors and at the tumor periphery has greatly promoted understanding of tumor access into the lymphatic system by inducing lymphangiogenesis or by co-opting preexisting lymphatics [2]. In contrast, impaired functioning of lymphatic vessels results in lymphedema as observed during breast cancer diagnosis and treatment [3-5].

During cancer progression, a bi-directional communication is established between the tumor microenvironment (TME) and lymphatic vessels. In one direction, the lymphatic vasculature alters TME by draining the interstitial protein-rich exudate fluid (lymph) into the bloodstream. In another direction, inflammation influences the composition and pressure of TME leading to altered lymphatic vessel function.

We choose to study bladder cancer because it represents 2% of all human malignancies. Urothelial carcinoma is one of the most common cancers – it ranks fifth among all cancers in the Western world, and there are 336,000 new cases and 132,000 deaths annually worldwide [6]. In the US alone, the American Cancer Society estimates that 50,040 men and 17,120 women will be diagnosed, and 13,060 men and women will die of cancer of the urinary bladder in 2007 [7]. Although the role of lymphatic vessels during bladder cancer progression is remarkably unknown, invasion of lymphatics during bladder cancer has been reported [8], whereas in prostate cancer there is a decrease in intratumoral lymphatic vessel density [9]. More recently, Fernandez and collaborators published the first manuscript suggesting the existence of proliferating lymph vessels and, therefore, of lymphangiogenesis in bladder transitional cell carcinoma (TCC), and proposed strong correlation of higher peritumoral LVD with the

presence of lymph nodes in clinically localized invasive bladder TCC [10]. However, up to now, no animal model was available for a systematic study of lymphatic vessel density and function during bladder cancer progression.

We previously described that a transgenic mouse (κ B-*lacZ*) with a reporter gene (*lacZ*) for NF- κ B presented constitutive β -galactosidase (β -gal) activity in all lymphatic endothelial cells [11] and that these mice serve a dual purpose by permitting both visualization of lymphatics and detection of constitutive and inducible NF- κ B activity [11]. To study in-depth the role of lymphatic vessels in bladder cancer progression, we generated a double transgenic mouse (SV40-*lacZ*) by crossing the κ B-*lacZ* mice with a well established model of bladder cancer (UPKII/SV40T) [12,13]. Here, we demonstrate that these SV40-*lacZ* mice present an increased lymphatic vessel density during bladder cancer progression.

We also show that a new compound, coined Gd-Cy5.5, which corresponds to a recently described contrast agent (biotin-BSA-Gd-DTPA) [14-16] conjugated to Cy5.5 permits dual imaging by near-infrared fluorescent (NIRF) and MRI. We, therefore, provide proof-of-concept that this contrast agent can be used for determination of lymphatic vessel function during bladder cancer progression.

Methods

Animals

All experiments were performed according to the "Principles for Research Involving Animals and Human Beings Guidelines" (OUHSC Animal Care & Use Committee protocol # 04-028). Double transgenic mice were obtained by crossing κ B-*lacZ* with UPKII/SV40T mice. The κ B-*lacZ* transgenic model used in this study was first described in 1996 [17] and enriched in the C57Bl/6 background. It was constructed using the promoter of the gene encoding p105, a precursor of the p50 subunit of NF- κ B. This promoter contains three NF- κ B binding sites in its proximal part driving the expression of *lacZ* with a nuclear localization sequence. These mice permit the visualization of lymphatic endothelial cells in the urinary bladder and all other tissues examined so far [17].

A double transgenic mouse model (SV40-lacZ) was generated by crossing the κB-lacZ transgenics with UPKII/SV40T mice. UPKII/SV40T mice present the SV40 large T antigen under the control of a urothelium-specific mouse uroplakin II promoter, and develop specifically bladder cancer [12,18,19]. The phenotype of each mouse was confirmed by southern blot analysis of SV40T and PCR for β-galactosidase in tail vein snips. Only double positive mice were used in these experiments. FVB mice were purchased from Jackson Labs, crossed with κB-lacZ, and used as controls for UPKII/SV40T mice.

Lymphatic Vessel Density (LVD)

We follow the "Reporting Recommendations for tumor Marker (REMARK)" guidelines [20]. This consensus report aims to lower the methodological variability of lymphangiogenesis quantification in tissue sections. The recommendations include: 1) double-blinded experiments; 2) the use of multiple IHC stains on serial sections (We used LYVE-1 IHC that has been established in our laboratories [11] and X-gal staining for β-galactosidase, because the SV40-lacZ enable this stain for visualization of lymphatic vessels [11]); and 3) the use of a double immunostaining of lymphatic marker and those for cell proliferation. In this context, bladder cross-sections were double stained with LYVE-1 and Ki-67 antibodies.

LVD in bladder whole-mounts

LVD was determined as described before [11,17]. Eight mice per point were euthanized with sodium pentobarbital (100 mg/kg, i.p.) and tissues were removed rapidly and stained as whole mounts with X-gal. β-galactosidase activity was revealed by X-gal staining at 30°C for 4–6 hours. Whole mounts were examined under a dissecting scope (SMZ 1500, Nikon). All tissues were photographed by a digital camera (DXM1200; Nikon). Exposure times were held constant when acquiring images from different tissues. Afterwards, tissues were washed four times in PBS and post-fixed in 2% paraformaldehyde in PIPES [piperazine diethanesulfonic acid]. Lymphatic vessel density was quantified by morphometric analysis using NeuroLucida workstation (MicroBrightField, Inc) [21], as described (ref [11]; supplemental material). Morphometric analysis was performed by importing NeuroLucida tracings into NeuroExplorer software version 3.70.2 (MicroBrightField, Inc) [21]. The ratio between the area occupied by lymphatics and the total tissue area (μm²) was then determined for each section and statistical analysis was performed using a Wilcoxon's rank sum test. Results are expressed as mean ± SEM. In all cases, a value of p < 0.05 was considered indicative of a significant difference [22]. This method may result in the overestimation of the lymphatic area. The software uses the 3D surface area of lymphatics, estimated from a 2D projection. Also, tissue area was calculated from a 2D projected cross-sectional tissue area (tissue contour).

phatics and the total tissue area (μm²) was then determined for each section and statistical analysis was performed using a Wilcoxon's rank sum test. Results are expressed as mean ± SEM. In all cases, a value of p < 0.05 was considered indicative of a significant difference [22]. This method may result in the overestimation of the lymphatic area. The software uses the 3D surface area of lymphatics, estimated from a 2D projection. Also, tissue area was calculated from a 2D projected cross-sectional tissue area (tissue contour).

Fluorescence IHC

Frozen bladders were processed for routine IHC according to published methods [23]. Frozen sections were post-fixed in 1% formaldehyde. All reagent incubations and washes were performed at room temperature. 5% normal donkey blocking serum (Jackson Immunolabs) was placed on all slides for 45 min and sections were incubated with primary antibody for 1 hour and 45 minutes in a humidifier chamber. Slides were washed 3 × 5 minutes in PBS and incubated with secondary antibodies. Slides were washed, counterstained with DAPI [4',6-diamidino-2-phenylindole; 1:20,000 dilutions of 10 mg/ml] for 2 minutes and coverslipped with Shur/Mount (TBS) mounting media and sealed with nail polish. All tissue cross-sections were visualized with a Nikon Eclipse TE 2000-S inverted fluorescent microscope (Nikon) [24] and imaged at room temperature using a digital CCD camera (Roper Scientific) [25], driven by NIS-Elements AR2.3 Imaging software (Laboratory Imaging/Nikon) [26]. Controls included omission of the primary antibody. Antibodies used in this work are listed in Table 1. All secondary antibodies were used at a 1:400 dilution. Secondary antibodies included donkey anti-rabbit IgG AF488 conjugate (Molecular Probes; probes.invitrogen.com), donkey anti-goat IgG (Alexa Fluor 546, A11056, Invitrogen), and donkey anti-rat IgG (AlexaFluore 488).

LVD and image analysis of bladder cross-sections

At least 6 random fields per cross-section were visualized at 20× magnification and used for image analysis that was performed with the NIS-Elements Advanced Research 2.3 imaging software [26]. This software identifies signal by thresholding key intensity values. Further the software permits imposing restrictions to the measurements by excluding false positive signals. Briefly, the number of

Table 1: Primary antibody characteristics

Antigen	Host Species	Against	Dilution	Code	Supplier
CD31	Rat	Mouse	1:50	550274	Abcam [67]
LYVE-1	Rabbit	Mouse	1:400	ab14917	Abcam [67]
Ki-67	Goat	Mouse	1:500	sc-7846	Santa Cruz [68]
MAC 387 (calprotein Ab-1) monoclonal	Mouse	Mouse	1:1000	Mac 387	Lab Vision [69]

positive cells expressing a particular antibody was calculated as percent of the region of interest (ROI), as indicated in the individual figure legend. Co-localization of two antibodies was calculated by converting the area occupied by cells positive for the first antibody into a ROI. Then the percent of cells that were positive for the second antibody was calculated within the ROI. Results are expressed as mean \pm SEM. In all cases, a value of $p < 0.05$ was considered indicative of a significant difference [22].

NIRF

Mice were fed a low-chlorophyll diet for 2 weeks to reduce auto-fluorescence in the intestinal region [27] and the abdominal hair was removed. Mice were anesthetized with isoflurane, placed in a heating pad, and received 200 μ L of the Gd-Cy5.5 intravenously, and the accumulation of Cy5.5 into the urinary bladder was followed over time. Anesthetized mice were immediately placed on a heating pad inside a FluorChem HD2 (Alpha Innotech, San Leandro, CA) equipped with a Chromalight[®] multi-wavelength illuminator and a 4-million pixel Cooled camera (F2.8 manual zoom lens and F1.4 fixed lens) coupled to a dedicated computer. The FluorChem cabinet permits continued anesthesia with isoflurane. Images were first acquired and stored with AlphaEase FC[®] 32-bit software (Alpha Innotech, San Leandro, CA) and subsequently, application of black-and-white and color gradients were performed in Adobe Photoshop[®] CS3 extended [28] that permitted the determination of integrated density. For this purpose, an elliptical marquee of fixed size (180 \times 180 px) was used to determine the region of interest (ROI) around the luminescence zones corresponding to a bladder area and the count tool was used to determine and record each integrated density. The integrated density corresponded to the sum of the values of the pixels in the ROI, which were equivalent to the product of the area (in pixels) and mean gray value.

MRI

All data was acquired using a Bruker 7 Tesla/30 cm horizontal bore magnet. Anatomical scans acquired proved to be useful in elucidating normal and bladder tumor tissue. Bladder and tumor physiology was followed in a time course study using this method at each time point, for each animal. This method is a dual spin-echo technique modified from a MSME (Multi-Slice Multi-Echo) technique designed to yield anatomical T1 and T2 weighted images for each slice position in the slice package. Axial scans acquired had the following parameters: TR = 900 ms, TE = 11.6 ms, slice thickness = 0.75 mm, NA = 4, slice gap = 0.05 mm, FOV = 2.5 cm \times 2.5 cm, matrix size = 256 \times 256, giving an in-plane resolution of 98 μ m \times 98 μ m. T1-weighted images had an effective TE of 17 ms, and T2-weighted images had an effective TE of 52 ms. Acquired parameter images had TE = 15 ms over a range of 5 TR

increments with values = (100, 300, 450, 600, 850, and 1150 ms), slice thickness = 0.75 mm (position of slice varied according to tumor location), FOV = 2.5 cm \times 2.5 cm, NA = 2, matrix size = 128 \times 128, and an in-plane resolution of 195 μ m \times 195 μ m. Mono-exponential fits were utilized to calculate actual T1 values in post-processing.

Synthesis of biotin-BSA-GdDTPA compound

The macromolecular contrast material, biotin-BSA-GdDTPA, was prepared by the modification of the method of Dafni and collaborators [29]. Bovine serum albumin (BSA, 0.5 g, 8 μ mol; Sigma) was dissolved in 0.1 M sodium bicarbonate (7.5 ml, pH 8.5). Sulfo-NHS-Biotin (22.4 mg; 53 μ mol; Pierce) was dissolved in double distilled water (DDW, 1.2 ml) and was added to BSA while stirring. The reaction mixture was stirred for 1 hr at 4°C and an additional 2 hrs at room temperature. The dialyzed product in 0.1 M Hepes buffer (pH 8.8) was reacted with diethylene triamine pentaacetic acid anhydride (DTPA, 0.5 g, 1.4 mmol; Sigma) suspended in 2.5 ml of dimethyl sulfoxide (DMSO) at room temperature. DTPA was added in portions and the pH was adjusted immediately after each addition to 8.5 with 5 N NaOH. The reaction mixture was stirred for 2 hrs at 4°C and extensively dialyzed against cold 0.1 M citrate buffer (pH 6.5). Finally, gadolinium (III) chloride (GdCl₃, 0.25 g; 0.67 mmol; Sigma) in 2.5 ml 0.1 M sodium acetate buffer (pH 6.0) was added gradually, and the mixture was stirred for 24 hrs at 4°C. The product, biotin-BSA-GdDTPA, was extensively dialyzed against cold citrate buffer (0.1 M, pH 6.5) and then against DDW. The product was lyophilized and stored at 4°C. For Cy5.5 -Gd preparation, 10 mg of dry lyophilized product (biotin-BSA-GdDTPA) was reconstituted in 150 μ l of sodium bicarbonate buffer 0.1 M pH 8.8 NaHCO₃. Cy5.5 dye (Cy5.5 mono functional reactive dye, Amersham Biosciences) was dissolved in 10–20 μ l of DMF and added to the product. The mixture was incubated in the dark at RT for 1 hr while mixing. The final compound biotin-BSA-GdDTPA-Cy5.5 was purified using Zeba 2 ml columns and had a molecular weight of \sim 82 kDa.

Other compounds

Dextran (500,000 MW)-Cy5.5 (Dex 0003–5) was purchased from Nanocs [30].

Results

Visualization of bladder lymphatics

As the parent mouse model (κ B-*lacZ*) permitted the visualization of lymphatic vessels by the expression of β -galactosidase, we investigated whether the double transgenic maintained this capacity. Figure 1A is a representative whole mount X-gal staining of bladders isolated from SV40-*lacZ* indicating that these mice maintained the constitutive activity of NF- κ B in lymphatic vessels. Positive X-




Figure 1

A-E. Visualization of lymphatic vessels in a double transgenic mouse model. SV40-*lacZ* mice obtained by crossing κ B-*lacZ* mice with UPKII/SV40 maintain the capacity of the parent mice in developing bladder carcinoma *in situ* (CIS) and labeling of bladder lymphatic vessels. **A** represents X-Gal staining of bladder whole mounts isolated from SV40-*lacZ* mice, indicating a rich network of lymphatic vessels in the bladder adventitia. Cross-sections of the urinary bladder illustrated in **A** were left unstained (**B**) or counter stained with H&E (**C-D**). Figure **C** is a representative of bladder adventitia and **D** is a high magnification of lymphatic vessels present in the detrusor smooth muscle. Arrows (**B, C, and D**) indicate the presence of β -galactosidase-positive lymphatic endothelial cells. **E** is a representative whole mount of bladders isolated from SV40-*lacZ* mice subsequently stained with X-gal to reveal β -galactosidase-positive cells (blue) and LYVE-1 IHC to reveal lymphatic endothelial cells (brown). Note the complete overlap of labels confirming constitutive NF- κ B activity in lymphatic vessels.

gal staining was also observed in cross sections left unstained (Figure 1B) or counter stained with H&E (Figure 1C and 1D). High magnification pictures of bladder cross sections indicate a nuclear localization of β -galactosidase expression in lymphatic endothelial cells due to a nuclear localization sequence of the original construct of the transgenic mouse (Figure 1D). Double staining of whole mounts confirmed that all β -galactosidase positive vessels were also LYVE-1-positive, and therefore, were lymphatic vessels (Figure 1E). In addition to lymphatic endothelial cells, cells morphologically resembling macrophages were the only other cell type that also showed LYVE-1 staining (Figures 2 A-C). This was further supported by the fact that these macrophage-like cells expressed MAC3, a macrophage marker [31] (Figures 2D-F). In contrast, other inflammatory cells were negative for LYVE-1 IHC. This is the case of mast cells present in the mouse bladder (Figure 2G-H).

Increased lymphatic vessel density (LVD) during mouse BC progression

Lymphatic vessel density was determined in control (FVB- κ B-*lacZ*) and SV40-*lacZ* mice by NeuroLucida® guided morphological analysis of LYVE-1 IHC stained bladder whole mounts, as described (supplemental material to manuscript [11]) and in cross-sections by fluorescent IHC. Figure 3A and 3B are representative LYVE-1 IHC of a urinary bladder isolated from SV40-*lacZ* mice. LYVE-1 staining was correlated with β -gal expression leading to results similar to those presented in Figure 1E and, therefore, indicating that the vessels represented in Figure 3A are indeed lymphatics. After IHC with LYVE-1 (Figure 3A) NeuroLucida® was used to trace and quantify the region of interest (ROI = white dotted line) and volume of lymphatic vessels (Figure 3B). Figure 3C presents the lymphatic vessel density (percent per unit of area) indicating that compared to 6-months old FVB- κ B-*lacZ* mouse ($n = 12$), SV40-*lacZ* mice ($n = 4$ for each time point) presented a significant increase in LVD in the adventitia during cancer progression (BC = mean LVD 39.3% ($n = 20$); and control (FVB- κ B-*lacZ* mice) = mean LVD 24.3%, [$n = 12$]; $p <$




Figure 2

Presence of LYVE-1-positive macrophages during bladder cancer progression. Representative photomicrographs indicating LYVE-1-positive cells resembling macrophages (red arrows) in the urinary bladders obtained from SV40-*lacZ* mice. **A** = LYVE-1 and Giemsa stain. **B** and **C** = LYVE-1 and H&E stained cross-sections. **D**, **E**, and **F** = MAC 387 immunohistochemistry (blue arrows) performed in serial sections of the same bladders represented in **A**, **B**, and **C**. Mast cells (black arrows) present in the cross-sections were positive for Giemsa stain, but negative for LYVE-1 (**D** and **E**).

0.001). This increase in LVD was observed in as young as 4-month old mice and remained elevated in all age groups studied so far (up to 9 months). Because LVD in whole mounts could only take into consideration medium and large lymphatics, an additional group of mice had their bladders removed and their cross-sections were studied by fluorescent IHC using LYVE-1 antibody. Image analysis of the cross-sections of 9-month old FVB- κ B-*lacZ* and SV40-*lacZ* mice (ages 7, 9, and 11 months) are presented in Figure 3D (a total of 11 control and 12 SV40-*lacZ* cross-sections were examined), confirming a significant increase in LVD during bladder cancer progression.

Bladder cancer-induced lymphangiogenesis

Next, the same cross-sections used for quantification of LYVE-1 were double labeled with LYVE-1 and an anti-goat polyclonal antibody against Ki-67(M-19), a nuclear protein expressed in proliferating cells that may be required for maintaining cell proliferation [32,33], and that provides the same value for proliferation index as BrdU in urothelial cancer cells [33]. Figure 4A–D is a representa-

tive photomicrograph of sub-urothelial lymphatic vessels illustrating the finding that some of the lymphatic endothelial cells were positive for both LYVE-1 and Ki-67. These results indicate the presence of cancer-induced lymphangiogenesis in this mouse model.

Lymphatic Vessel Function (LVF) by NIRF

For NIRF, a total of 9 SV40-*lacZ* mice ages 6–11 months were used. Mice were fed a low-chlorophyll diet for 2 weeks to reduce auto-fluorescence in the intestinal region [27] and the abdominal hair was removed. Mice were anesthetized with isoflurane and received 200 μ L Gd-Cy5.5 intravenously (dose of 500 mg/kg), and the accumulation of Cy5.5 into the urinary bladder was followed over time.

A time-course of Cy5.5 accumulation in the lower abdominal region of SV40-*lacZ* is illustrated in Figures 5A–5F. Additional mice, represented in Figures 5G–J, have their abdomen opened and the gastrointestinal tract removed to permit better visualization of the pelvic floor. Near




Figure 3

Increased lymphatic vessel density during bladder cancer progression. LYVE-1 IHC quantification of lymphatic vessel density (LVD) in bladders isolated from control and SV40-*lacZ* mice. **A** = Representative photomicrographs of LYVE-1 IHC. **B** = NeuroLucida tracing of lymphatics. **C** = Lymphatic vessel density during cancer progression in whole mount preparations of LYVE-1 stained bladders isolated from SV40-*lacZ* mice compared to control (FVB-κB-*lacZ* = pink). **D** = Lymphatic vessel density during cancer progression in cross-section preparations of LYVE-1 stained bladders isolated from SV40-*lacZ* mice compared to control (FVB-κB-*lacZ* = pink). Asterisks indicate a statistical significant difference ($p < 0.05$) between FVB-C57BL/6 and SV40-*lacZ* mice.

infra red fluorescence of the regions within red circles on Figures 5A–F is represented as integrated density in Figure 5K. The numbers in each segment indicate the time lapse after i.v. administration of Gd-Cy5.5. An absence of specific fluorescence in the lower abdominal regions of mice

at zero and 10 min after Gd-Cy5.5 administration (Figure 5A and 5B) is observed. A gradual accumulation of Cy5.5 was observed and a fluorescence peak occurred in the bladder region at 120 minutes (Figure 5B and 5F). At 240 minutes a significant amount of fluorescence still




Figure 4

Bladder cancer-induced lymphangiogenesis. Next, the same cross-sections illustrated in Figure 3 were double-labeled with antibodies against LYVE-1 and a marker of cell proliferation, Ki-67. **A–D** are representative photomicrographs of the sub-urothelial lymphatic vessels illustrating the finding that some of the lymphatic endothelial cells were positive for both LYVE-1 (green fluorescence in **B**) and cell proliferation (Ki-67-positive cells are in red fluorescence in **C**), as illustrated by a yellow labeling of merged images in **D**. These results indicate the presence of cancer-induced lymphangiogenesis in this mouse model. Blue stain in **A** is DAPI (4,6-diamidino-2-phenylindole) which highlights the cell nuclei.




Figure 5
Lymphatic Vessel Function (LVF) by NIRF. For NIRF, a total of 9 SV40-*lacZ* mice ages 6–11 months were used. Mice were fed a low-chlorophyll diet for 2 weeks to reduce auto-fluorescence in the intestinal region and the abdominal hair was removed. Mice were anesthetized with isoflurane and received 200 μ L Gd-Cy5.5 intravenously (dose of 500 mg/kg), and the accumulation of Cy5.5 into the urinary bladder was followed over time (A–F). Additional mice, represented in G–J, have their abdomen opened and the gastrointestinal tract removed to permit better visualization of the pelvic floor. NIRF of the regions within red circles on A–F is represented as average \pm SEM of the integrated density $\times 10^7$ (K). The numbers in each segment indicate the time lapse after i.v. administration of Gd-Cy5.5. Outside the urinary bladder, Cy5.5 accumulated in the kidneys (green arrows) and in lymph sacs (blue arrows in G, I, and J).


remained in the urinary bladder (Figure 5C and 5G). At 330 minutes the urinary bladders revealed low NIRF (Figure 5E and 5I) when compared to the fluorescence peak observed at 120 minutes, and at 24 hours (1440 min) only residual fluorescence was observed (Figure 5J). In addition, it should be noted that emptying the residual urinary content of the bladder did not alter significantly the intensity of fluorescence, indicating that the residual fluorescence corresponded to Cy5.5 which still remained within the bladder parenchyma. Outside the urinary bladder, Cy5.5 accumulated in the kidneys (green arrows) and in lymph sacs (blue arrows in Figures 5G, 5I and 5J).

Co-localization of Cy5.5 with LYVE-1 positive lymphatics and CD31-positive blood vessels

To confirm the results obtained *in vivo*, groups of mice (n = 3) were euthanized at 2, 5.5, and 24 hours (120, 330, and 1440 minutes) after i.v. administration of Gd-Cy5.5

and the bladders were removed for analysis of co-localization of Cy5.5 with LYVE-1- and CD31-positive cells. Figures 6, 7, 8 contain representative photomicrographics of confocal analysis of bladder cross-sections and the results of image analysis performed in all sections are presented in Figure 9. In all figures, the red represents Cy5.5 accumulation and the blue stain is DAPI (4',6-diamidino-2-phenylindole), which highlights the cell nuclei. The yellow label indicates co-localization of Cy5.5 with CD31-positive blood vessels, or LYVE-1-positive lymphatic vessels.

In particular Figures 6 A–B and 7 A–B indicate the suburothelial localization of blood vessels whereas lymphatic vessels are seen in the deeper regions of the mucosa but not in the subepithelial layer. Figures 8 A–D indicate that, at 1140 minutes, a significant amount of Cy5.5 still remains in the bladder parenchyma which may explain the fluorescence observed in Figure 5K.


**Figure 6**

Distribution of Cy5.5 between blood and lymphatic vessels at 120 minutes after administration of Gd-Cy5.5. To confirm the results obtained *in vivo*, groups of mice ($n = 3$) were euthanized at 120 minutes after i.v. administration of Gd-Cy5.5 and the bladders were removed, frozen, and prepared for confocal analysis of the co-localization of Cy5.5 with CD31-positive vessels (green fluorescence in **A** and **C**) or LYVE-1-positive lymphatic vessels (green fluorescence in **B** and **D**). **A** and **B** are representative microphotographs of the same sub-epithelial region, whereas **C** and **D** are representative photomicrographs of the detrusor smooth muscle. Note that blood vessels are just underneath the urothelial cell layer (**A**), whereas lymphatic vessels are deeper in the submucosa (**B**). The white arrows in **A** indicate Cy5.5 (red) that is co-localized with LYVE-1-positive cells in **B** (yellow arrows). The cyan arrow in **B** indicates Cy5.5 (red) that is co-localized with CD31-positive blood vessels in **A** (orange arrows). In all figures, the red represents Cy5.5 accumulation and the blue stain is DAPI. The yellow fluorescence indicates co-localization of Cy5.5 with CD31-positive blood vessels (**A**) or LYVE-1-positive lymphatic vessels (**B**). Quantification of the fluorescent signals by image analysis is presented in **Figure 9**.

Image analysis indicates that at all time points the area of the bladder cross-sections occupied by CD31-positive blood vessels was greater than the area occupied by LYVE-1-positive lymphatic vessels (Figure 9). In terms of co-localization of Cy5.5, at 120 minutes, Cy5.5 was found evenly distributed between LYVE-1-positive lymphatics and CD31-positive blood vessels (Figure 9). At 330 minutes a great proportion of Cy5.5 was found within LYVE-1-positive lymphatic vessels, and at 1140 minutes, most of the Cy5.5 was found within lymphatic vessels (Figures 9). These results provided the basis for subsequent MRI analysis of lymphatic vessel function.

NIRF visualization of abdominal large lymphatic vessel draining the urinary bladder

A constant feature observed following i.v. administration of Cy5.5-conjugates was the labeling of abdominal lymphatic sacs (blue arrows in Figures 5G, 5I, and 5J). In order to investigate whether NIRF would permit visualization of these collecting lymphatic vessels and lymph sacs, high molecular weight dextran (500,000 MW)-Cy5.5 was injected in the pelvic floor underneath the urinary bladder, in the same region of lymph sacs of anesthetized mice and serial images were immediately captured. Figures 10 A–D are negative NIRF images acquired along with time and indicate the movement of Cy5.5 in major collecting lymphatic vessels and Figures 10E and 10F are higher magnifications of the same system. It was noted that a series of lymph sacs were observed squirting the fluores-

**Figure 7**

Distribution of Cy5.5 between blood and lymphatic vessels at 330 minutes after administration of Gd-Cy5.5. Photomicrographs obtained 330 minutes after i.v. administration of Gd-Cy5.5. **A** and **B** are representatives of the urothelial region whereas **C** and **D** are representatives of the adventitial region. Arrow's color scheme, as described in Figure 6. Quantification of the fluorescent signals by image analysis is presented in Figure 9.

cent content rhythmically and upwards (black and white arrows indicate the direction of the flow in two major collecting lymphatic vessels). A quick time movie (Additional File 1), illustrates the upward movement of Cy5.5 within collecting lymphatic vessels shown in Figure 11.

Two hours after dextran-Cy5.5, the abdomen was opened and the gastrointestinal tract was removed, and representative photomicrographs were taken in black-and-white (Figure 12A) or artificially-colored to provide a gradation of fluorescence distribution (Figure 12B). It can be noticed that Cy5.5 accumulation occurred primarily in the bladder, uterus, and lymph sac or cysterna. NIRF also permitted the guided capture of tissues or organs with high fluorescence intensity. In this way, lymph sacs were dissected under fluorescence and processed for histology. Figure 12C is a composite of a cross-section of a lymph sac showing an interesting pattern of concentric paths of smooth muscle (black dotted circle) that can be appreci-

ated at higher magnification in Figure 12D. A region with high concentration of lymphocytes was also visible (wavy black line on Figure 12C) and at the confocal level, it was possible to determine the presence of CD-31-positive blood vessels (Figure 12E; green) and LYVE-1-positive lymphatic vessels (Figure 12F; green) draining this region. In both figures, the red represents Cy5.5 accumulation and the blue stain is DAPI.

Although this work is very preliminary, it permitted our laboratory to identify and measure lymphatic function *in vivo* and in real time. These results indicate that NIRF can be used to study how Cy5.5-conjugate compounds are distributed between the interstitial fluid, blood vessels, and lymphatics. Figure 5K illustrates the kinetics of Gd-Cy5.5 and permitted the follow up of lymphatic vessel function by MRI (see below). In addition, large collecting lymphatics can be identified, the propulsion of lymph within lymphatic vessels can be visualized, and movies can be used




Figure 8

Distribution of Cy5.5 between blood and lymphatic vessels at 1440 minutes after administration of Gd-Cy5.5. Photomicrographs obtained 1440 minutes after i.v. administration of Gd-Cy5.5. **A** and **B** are representatives of the urothelial region, whereas **C** and **D** are representatives of the adventitial region. Arrow's color scheme, as described in **Figure 6**. Quantification of the fluorescent signals by image analysis is presented in **Figure 9**.

to study these dynamics (Figure 11). Finally, NIRF-guided capture permitted us to start observing collecting lymphatics and lymph sacs and, therefore, to further study their structures.

Magnetic Resonance Imaging of mouse urinary bladder cancer

Thanks to a unique rodent-dedicated MRI facility on campus [34], we were able to meet two major goals regarding the SV40-*lacZ* mice. The first goal was to detect the presence of BC as early as possible. This permitted a longitudinal study of tumor sizes during cancer progression. The second goal was to determine whether the observed increase in LVD was accompanied by an increased lymphatic function. A total of 7 SV40-*lacZ* mice and 3 wild type controls (FVB crossed with κ B-*lacZ* mice) entered the study. Out of the 7 SV40-*lacZ* mice, 5 developed bladder tumors and 1 had to be euthanized.

We were successful in early bladder cancer detection, and MRI technology permitted the detection of bladder cancer as early as in 6 months (youngest animal scanned). Figures 13, 14, and 15 are representative double echo MRIs of 6-month old SV40-*lacZ* mouse bladder. Additional file 2 is a movie obtained during pre-contrast MRI indicating the different scanning positions (Figure 13). Additional file 3 is a post-contrast (Gd-Cy5.5) MRI movie that is highlighted in Figure 14. Figure 15 is a detail of the last frame of movie presented in additional file 3 (a red circle delimits the urinary bladder and waved green line delimits tumor areas that are darker than the normal tissue). Overall, the urinary bladders averaged volumes of $219.2 \pm 74 \text{ mm}^3$. In contrast, the total area of the tumors averaged $0.31 \pm 0.1 \text{ cm}^2$, occupying areas of $31 \pm 12.7 \text{ mm}^2$ and volumes of $15.6 \pm 6 \text{ mm}^3$. The smallest bladder tumor detected by MRI had a volume of 2.1 mm^3 . The tumor fractional volume in comparison with the whole bladder averaged $0.11 \pm 0.02\%$. Longitudinal studies indicated




Figure 9
Image Analysis of bladder cross-sections obtained at 120, 330, and 1440 minutes (n = 3 mice per time point). Six random fields per cross-section were visualized at 20× magnification and used for image analysis that was performed with the NIS-Elements Advanced Research 2.3 imaging software (see Methods). Results are presented as mean and SEM. Asterisks indicate a statistically significant difference (p < 0.05) between the bladder area covered by blood vessels (CD-31) and lymphatic vessels (LYVE-1), whereas a pound sign indicates a statistically significant difference (p < 0.05) between the distribution of Cy5.5 in CD-31-positive blood vessels and LYVE-1-positive lymphatic vessels.

that in some mice the tumor tripled its initial volume over 2 months (Figure 16).

Dynamic contrast-enhanced MRI and Gd-Cy5.5 for determination of LVF

Dynamic contrast-enhanced MRI (DCE-MRI) images with the use of the contrast agent Gd-Cy5.5 were acquired subsequent to anatomical scans providing sensitive regions of interest (ROI) for calculating T1 values between normal and bladder tumor relaxation times. We found an increased signal (due to decreased T1 relaxation) that correlated with an increased uptake of the Gd-probe from the blood vessels into the urinary bladder extra vascular space. The bladder volume did not change significantly during the imaging period. However, there may have been some motion artifacts associated with respiratory motion that was not compensated with respiratory gating. Figure 17A is a gray scale representation of peak accumulation of the Gd-probe in the bladder wall, except within tiny regions (a red circle delimits the urinary bladder and green lines indicated two tumor areas that are darker than the normal tissue). Figure 17B represents the difference image obtained at 30 minutes post-Gd-probe contrast subtracted from the pre-contrast image. This image illustrates an early enhancement by the contrast agent into the urinary bladder extravascular space, which may be attributed to vascular leakage. Figure 17C represents difference image obtained at 80 minutes post-contrast subtracted




Figure 10
NIRF visualization of abdominal large lymphatic vessel draining the urinary bladder. A constant feature observed following i.v. administration of Cy5.5-conjugates was the labeling of abdominal lymphatic sacs (blue arrows in **Figures 5G, 5I, and 5J**). In order to investigate whether NIRF would permit visualization of these collecting lymphatic vessels and lymph sacs, high molecular weight dextran (500,000 MW)-Cy5.5 was injected in the pelvic floor underneath the urinary bladder, in the same region of lymph sacs of anesthetized mice, and serial images were immediately captured. **Figures 10 A-D** are negative NIRF images acquired along with time and indicate the movement of Cy5.5 in major collecting lymphatic vessels. It was noted that a series of lymph sacs were observed squirting the fluorescent content rhythmically and upwards (black and white arrows indicate the direction of the flow in two major collecting lymphatic vessels). A quick time movie, **Figure 10 E** illustrates the upward movement of Cy5.5 within collecting lymphatic vessels. **Figures 10 F** and **10 G** are a high magnification of an individual frame of the movie illustrated in Figure 11 and additional file 1.




Figure 11
Isolated frame of a movie (additional file 1) presenting the visualization of high molecular weight dextran (500,000 MW)-Cy5.5 by NIRF.

from 30 minutes post-contrast. This image demonstrates a delayed enhancement due to drainage and pooling of the contrast agent, which may reflect uptake within the lymphatics in the bladder. Figure 17D represents the difference image obtained between images in 17B and 17C (80 min. post-contrast minus 30 min post-contrast, and the 30 min. post-contrast minus the pre-contrast images). This image suggests that there is decreased drainage within tumorigenic areas and perhaps a pronounced increase in uptake in the lymphatics within normal regions.

Because drainage of macromolecules by the lymphatics is a slow event with rates of 2.3 to 3.7 $\mu\text{l/g}$ minutes, images were acquired in two "phases" corresponding to the biphasic kinetics of the BSA-Gd-DTPA [15]. The first or "early phase" is comprised of images obtained just before i.v. administration of 200 μL Gd-Cy5.5 (dose of 500 mg/kg). Starting at 3 minutes post-injection, images were acquired every 7 minutes, up to 2 hours post-contrast. The second block of MRI data was acquired up to 80 minutes after the first series of images. A digital subtraction of the images between pre- and 80 minutes post-contrast follow-




Figure 12
NIRF-guided capture of lymph sacs. Dextran-500,000 MW-Cy5.5 was administered in the pelvic floor underneath the urinary bladder. Two hours after dextran-Cy5.5, the abdomen was opened and the gastrointestinal tract was removed, and representative photomicrographs were taken in black-and-white (A) or artificially-colored to provide a gradation of fluorescence distribution (B). Fluorescent lymph sacs (white circle in A and B) were captured and dissected under fluorescence, and subsequently frozen for histology. C is a composite of an H&E stained cross-section (originally at $\times 100$) of a lymph sac showing an interesting pattern of concentric paths of smooth muscle (dotted black circle) that can be appreciated at higher magnification in D. A region with high concentration of lymphocytes was also visible (wavy black line in figure C). This region was processed for fluorescent Immunohistochemistry and at the confocal level, it was possible to determine the presence of CD-31-positive blood vessels (E; green) and LYVE-1-positive lymphatic vessels (F; green) draining this region. In figures E and F, the red represents Cy5.5 accumulation and the blue stain is DAPI. Original magnifications were: C = $\times 100$, D = $\times 400$, E = $\times 400$, and F = $\times 400$.



Figure 13
Double echo pre-contrast MRI. This is a representative frame of a double echo MRI of 6-month old SV40-lacZ mouse bladder indicating the different scanning positions. A movie is illustrated in additional file 2.




Figure 15
 Detail of the last frame of movie presented in Figure 14 (additional file 3) indicating the urinary bladder (red circle) and tumor areas that are darker than the normal tissue (waved green line delimit tumor areas).




Figure 14
Double echo post-contrast MRI. This is a representative frame of a double echo MRI obtained in the same mouse bladder represented in Figure 13 after injection of Gd-Cy5.5. A movie is illustrated in additional file 3.

ing Gd-Cy5.5 in three contiguous slices from the same bladder (positions -0.2, -0.8, and +0.8) was artificially colored (Figures 18A, 18B, and 18C). The red and yellow regions are active lymphatic vessels and consist of drainage events within the bladder interstitium. Figure 19 represents the comparison between tumor-bearing bladders (Figure 19A) and controls (Figure 19B and 19C). T1 values from these regions were normalized as percent of the reference site (muscle). This figure represents the time-dependent clearance of the contrast agent away from the bladder and provides a strong indication of LVF. Note the difference in T1 values between a tumor region and an adjacent normal bladder region (Figure 19A). In control bladders, two different normal regions were compared. These results suggested decreased drainage in the areas bearing tumors in comparison to normal areas.

Discussion

Our results with SV40-lacZ mice indicate that in the normal bladder, a rich lymphatic vessel network is visible from the adventitia through the detrusor smooth muscle. It is characterized as a vascular network of blind ended, thin-walled capillaries that merge to larger collecting ducts, all positively stained with LYVE-1 antibody. In sharp contrast with the dense blood vessel vascularization of the bladder mucosa, we found that lymphatic vessels are absent of the sub-urothelium being located much




Figure 16

Longitudinal studies of tumor size during the period of 2 months (n = 5). Mean and SEM values for tumor volume, bladder volume, and fractional tumor volume obtained from five SV40-*lacZ* mice developing bladder tumor.

deeper in the lamina propria (Figures 6A, 6B, 7A, and 7B) which seems to parallel the clinical findings in the human bladder [35,36].

Our analysis indicates an increased lymphatic density during cancer progression and a co-localization of Ki-67 with some of LYVE-1-positive lymphatics, suggesting cancer-induced lymphangiogenesis (Figure 4), as it was recently suggested in human bladder cancer [10,37]. However, the mechanisms for bladder lymphangiogenesis are not clear. In contrast to blood vessel angiogenesis, the mechanisms of lymphangiogenesis in general are still relatively vague [38]. Vascular endothelial growth factor-C (VEGF-C) and VEGF-D have been implicated as specific regulators of lymphangiogenesis [39-43]. Both growth factors mediate their biological activity mainly by VEGF receptor-3 (VEGFR-3, Flt-4) [44,45]. It remains to be determined whether VEGF-C and VEGF-D along with VEGFR-3 play a role in lymphangiogenesis during bladder cancer development. Another interesting line of research involves LYVE-1-positive tumor associated macrophages [46] that have indeed been associated with tumor lymphangiogenesis [47,48]. In the eye, a stepwise mechanism of inflamma-

tion-associated *de novo* lymphangiogenesis involves potential lymphatic progenitor cells [49] derived from circulation that transmigrate through the connective tissue stroma, presumably in the form of macrophages [49-51], and finally incorporate into the growing lymphatic vessels [52]. Our present findings indicate that in addition to LYVE-1-positive lymphatic endothelial cells, during bladder cancer development, LYVE-1 positive macrophages were found in the bladder detrusor muscle isolated from SV40-*lacZ* mice. Although this may be only a circumstantial finding, it opens a testable hypothesis on the role of macrophages and other inflammatory cells in bladder lymphangiogenesis. The introduction of SV40-*lacZ* along with the visualization and quantification techniques described here will permit further investigation on this subject.

It has been proposed that lymphangiogenesis is correlated with tumor metastasis. Increasing knowledge of the tumor's biological significance in lymphatics within the tumors (intratumoral lymphatics, ITLs) and at the tumor periphery (peritumoral lymphatics, PTLs) has greatly promoted understanding of tumor access into the lymphatic system by inducing lymphangiogenesis or by co-opting preexisting lymphatics [2]. Indeed, peritumoral lymphatics have also been associated with both regional metastasis and survival in bladder [37], lung [53], breast [54], and prostate cancer [55]. But the question still remains as to whether pre-existing vessels are sufficient to serve this function, or whether tumor cell dissemination requires *de novo* lymphatic formation or an increase in lymphatic size. In this regard, Fernandez and collaborators reported that in the human bladder, higher intratumoral LVD correlates significantly with poor histological differentiation, and that higher peritumoral LVD showed a significant association with the presence of lymph node metastasis [10]. Although peritumoral lymphatic vessels contribute to tumor metastasis, opposite views exist as to whether intratumoral lymphatics have any role in tumor metastasis [56,57]. Padera and collaborators examined functional lymphatics associated with mouse tumors expressing normal or elevated levels of VEGF-C [58]. Although VEGF-C over-expression increased lymphatic surface area in the tumor margin and lymphatic metastasis, these tumors contained no functional lymphatics, as assessed by four independent functional assays and IHC staining [58]. These findings suggest that the functional lymphatics in the tumor margin alone are sufficient for lymphatic metastasis and should be targeted therapeutically [58]. Our MRI results are in agreement with those described by Padera and collaborators [58] in the sense that intratumoral lymphatic vessels have a reduced function when compared to normal areas of the bladder.




Figure 17
MRI of mouse bladder using Gd-Cy5.5 as contrast agent. **A.** Gray-scale image of the bladder and tumors at pre-contrast before Gd-probe administration. **B.** Difference image obtained at 30 minutes post-Gd-probe contrast subtracted from the pre-contrast image. This image demonstrates an early enhancement by the contrast agent into the urinary bladder extravascular space, which may be attributed to vascular leakage. **C.** Difference image obtained at 80 minutes post-contrast subtracted from 30 minutes post-contrast. This image demonstrates a delayed enhancement due to drainage and pooling of the contrast agent, which may reflect uptake within the lymphatics in the bladder. **D.** Difference image obtained between images in **B** and **C** (80 min. post-contrast minus 30 min post-contrast, and the 30 min. post-contrast minus the pre-contrast images). This image suggests that there is decreased drainage within tumorigenic areas, and perhaps a pronounced increase in uptake in the lymphatics within normal regions.




Figure 18
Digital subtraction of the images between pre- and 80 minutes post-contrast. Images were acquired in two "phases" corresponding to the biphasic kinetics of the BSA-Gd-DTPA [15]. The first or "early phase" comprised of images obtained just before i.v. administration of 200 μ L Gd-Cy5.5 (dose of 500 mg/kg). Starting at 3 minutes post-injection, images were acquired every 7 minutes, up to 2 hours post-contrast. The second block of MRI data was acquired up to 80 minutes after the first series of images. Images represent accumulation of Gd-Cy5.5 represented in three contiguous slices from the same bladder (positions -0.2 = A, -0.8 = B, and +0.8 = C). The red and yellow regions are active lymphatic vessels and consist of drainage events within the bladder interstitium.




Figure 19

Time-dependent clearance of the Gd-probe agent away from the bladder provides a strong indication of lymphatic vessel function (LVF). **Figure 18** represents the comparison between tumor-bearing bladders (**Figure A**) and controls (**Figures B and C**). Data represents T1 values in [ms] with Bruker's MSMEVTR spin-echo method, including 3 slice packages chosen to include both normal and tumor regions in bladder. T1 values from these regions were normalized as percent of the reference site (muscle). In control bladders, two different normal regions were compared. This figure represents the time-dependent clearance of the contrast agent away from the bladder and provides a strong indication of LVF. Asterisks indicate a statistical significant difference ($p < 0.05$) between normal and tumor areas.

Another question answered by the present work was whether an increase in the number of lymphatic vessels leads to increased function. For this purpose, we followed the strategy recently reviewed by Neeman and collaborators [59]. The contrast agent introduced here was originally described by Dafni and collaborators [14-16], and subsequently by Pathak and collaborators [15], for visualization of lymphatics and determination of their function. The modification of conjugating biotin-BSA-Gd-DTPA [15] to Cy5.5 permitted us to use NIRF and MRI to follow the dynamics of the same compound and calculate lym-

phatic vessel function. The advantage of using NIRF is the faster time for data acquisition. NIRF information permitted us to narrow the number of time points for subsequent MRI studies.

The proposed mechanism of visualization of BSA-Gd-Cy5.5 (~82 kDa) is based on the presence of BSA which prolongs its lifetime in circulation. Initially the probe is confined to blood vessels and it is systemically distributed, and as the time passes it extravasates to the extracellular space in points of increased vascular permeability.

Both NIRF and MRI are able to detect when BSA-Gd-cy5.5 starts to accumulate in the extracellular space and when its accumulation reaches a plateau. This was done at the MRI level by following the longitudinal relaxation rates ($1/T_1$) that correlates with increased uptake of the Gd-probe from the blood vessels into the urinary bladder extra vascular space. This phase was called the "early phase" in this manuscript. After 80 minutes of the plateau, a second series of MRI were started and followed the clearance of BSA- Gd-Cy5.5 from the extravascular by the lymphatic vessels. This was supported by *ex vivo* images which indicated that, at this point, most of the BSA-Gd-Cy5.5 is drained from the tissue by lymphatic vessels.

Although MRI lymphangiography does measure areas of draining and pooling instead of directly evaluating lymphatic vessel function, the delayed enhancement observed at later time points from the Gd-probe may also reflect uptake of Gd-probe in the lymphatics. In addition, this information can not be obtained any other way and clinical studies attest the validity of using lymphangiography for assessment of lymphatic vessel function [60-64]. A step forward in this direction was introduced here by the use of a single probe that can be imaged by MRI and NIRF. The first indicates areas of draining and pooling and the second permitted the temporal association of images with cross-sections indicating the relative distribution of the probe between CD31-positive blood vessels and LYVE-1-positive lymphatic vessels.

As pointed out by Neeman and collaborators [59], contrast MRI data are typically dominated by vascular permeability, which often masks the relatively slow lymphatic drain. To separate vascular leakage from the lymphatic drain, an avidin chase needs to be introduced [14,16] which through the rapid clearance of intravenously administered biotin-BSA-Gd-DTPA, allowed them to experimentally track interstitial convection and lymphatic drain in the absence of continuing vascular leakage [14,16]. Our present MRI results are not corrected for vascular leakage. Therefore, future experiments will take into consideration this point for a more detailed analysis of lymphatic vessel function using the advantage of the presence of biotin in the Gd-Cy5.5 molecule.

Another advantage of NIRF was to permit the collection of tissues exhibiting fluorescence. In this regard, we were able to further pursue the morphology of lymph sacs using dextran-Cy5.5. This will allow us in the near future to determine the contractility of lymph sacs and abdominal lymphatic vessels. The rhythmic activity observed in the abdominal lymphatics draining the urinary bladder is in agreement with recent results that indicated that mesenteric lymphatic vessels have a true pacemaker mechanism [65,66]. The experiment described in Figures

10, 11, 12 will permit the capture and evaluation of large lymphatic function in health and disease.

Conclusion

The present work introduces a new double transgenic mouse model that permits the visualization of lymphatic vessels during bladder cancer progression, and introduces new technologies for the visualization and quantification of lymphatic vessel density and function by combining NIRF and MRI imaging. The results presented here raise the possibility of the study of lymphatic vessel activity *in vivo* and in real time and raises the hypothesis regarding the role of lymphangiogenesis during bladder cancer progression. It remains to be determined whether manipulation of lymphatic vessel density and function would alter bladder tumor progression.

Abbreviations

IHC, immunohistochemistry; MRI, magnetic resonance imaging; and NIRF, near infrared fluorescence.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

All authors read and approved the final manuscript. MRS conceived study and experimental design, participated in NIRF experiments, performed IHC analysis, interpreted the results, and drafted the manuscript; RT performed MRI experiments, participated on the design, results interpretation, and helped drafting the manuscript; NS synthesized the d-Cy5.5; AA performed MRI experiments and interpretation of MRI results; MN consulted MRS regarding the proper contrast agents, participated in the design of MRI experiments and interpretation of the results, and helped drafting the manuscript; CAD maintained the genotyping and animal colony, and performed image analysis; CS performed animal experiments and whole mount IHC; JM participated on the design of immunohistochemistry protocols and choice of antibodies, performed the immunohistochemistry and confocal microscopy analysis; SM developed kB-lacZ mice, participate in the design of the double transgenic, and helped drafting the manuscript; X-RW developed UPKII-SV40T mice, participate in the design of the double transgenic, and helped drafting the manuscript; and RS participated in the experimental design, performed NIRF experiments and data interpretation.

Additional material

Additional File 1

Large lymphatics draining the lower urinary tract. Quick time movie presenting the visualization of high molecular weight dextran (500,000 MW)-Cy5.5 by NIRF injected in large collecting lymphatics draining the lower urinary tract.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-7-219-S1.mov>]

Additional File 2

Movie obtained during pre-contrast MRI. This is a representative double echo MRI of 6-month old SV40-lacZ mouse bladder indicating the different scanning positions.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-7-219-S2.mov>]

Additional File 3

Movie obtained post-contrast MRI. This is a representative double echo MRI obtained in the same mouse bladder represented in Figure 14 after injection of Gd-Cy5.5.

Click here for file

[<http://www.biomedcentral.com/content/supplementary/1471-2407-7-219-S3.mov>]

Acknowledgements

This work was supported the Oklahoma Center for the Advancement of Science & Technology (OCAST) – Project HRO4-135S- (MRS), National Institutes of Health grants 5R01 DK066101-02 (RS) and 5R01 DK055828-05 (RS), and Israel Science Foundation (MN).

References

- Ji RC: **Lymphatic endothelial cells, inflammatory lymphangiogenesis, and prospective players.** *Curr Med Chem* 2007, **14(22)**:2359-2368.
- Ji RC: **Lymphatic endothelial cells, tumor lymphangiogenesis and metastasis: New insights into intratumoral and peritumoral lymphatics.** *Cancer Metastasis Rev* 2006, **25(4)**:677-694.
- Armer J, Fu MR, Wainstock JM, Zagar E, Jacobs LK: **Lymphedema following breast cancer treatment, including sentinel lymph node biopsy.** *Lymphology* 2004, **37(2)**:73-91.
- Armer JM: **The problem of post-breast cancer lymphedema: impact and measurement issues.** *Cancer Invest* 2005, **23(1)**:76-83.
- Pain SJ, Barber RW, Solanki CK, Ballinger JR, Britton TB, Mortimer PS, Purushotham AD, Peters AM: **Short-term effects of axillary lymph node clearance surgery on lymphatic physiology of the arm in breast cancer.** *J Appl Physiol* 2005, **99(6)**:2345-2351.
- Parkin DM, Bray F, Ferlay J, Pisani P: **Estimating the world cancer burden: Globocan 2000.** *Int J Cancer* 2001, **94(2)**:153-156.
- Cancer Facts & Figures** [<http://www.cancer.org/downloads/STT/CAFF2007PVVSecured.pdf>]
- Moyano Calvo JL, Ortiz Gamiz A, Poyato Galan JM, Gutierrez Gonzalez M, Sanchez Sanchez E, Alvarez-Ossorio Fernandez JL, Castineiras Fernandez J: **[Lymphatic invasion of the bladder wall in T1 superficial bladder carcinoma. Prognostic value].** *Actas urologicas espanolas* 2003, **27(4)**:260-264.
- Trojan L, Michel MS, Rensch F, Jackson DG, Alken P, Grobholz R: **Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1).** *J Urol* 2004, **172(1)**:103-107.
- Fernandez MI, Bolenz C, Trojan L, Steidler A, Weiss C, Alken P, Grobholz R, Michel MS: **Prognostic Implications of Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the Bladder.** *Eur Urol* 2007.
- Saban MR, Memet S, Jackson DG, Ash J, Roig AA, Israel A, Saban R: **Visualization of lymphatic vessels through NF-kB activity.** *Blood* 2004, **104(10)**:3228-3230.
- Zhang ZT, Pak J, Shapiro E, Sun TT, Wu XR: **Urothelium-specific expression of an oncogene in transgenic mice induced the formation of carcinoma in situ and invasive transitional cell carcinoma.** *Cancer Res* 1999, **59(14)**:3512-3517.
- Wu XR: **Urothelial tumorigenesis: a tale of divergent pathways.** *Nat Rev Cancer* 2005, **5(9)**:713-725.
- Dafni H, Israely T, Bhujwala ZM, Benjamin LE, Neeman M: **Overexpression of vascular endothelial growth factor 165 drives peritumor interstitial convection and induces lymphatic drain: magnetic resonance imaging, confocal microscopy, and histological tracking of triple-labeled albumin.** *Cancer Res* 2002, **62(22)**:6731-6739.
- Pathak AP, Artemov D, Ward BD, Jackson DG, Neeman M, Bhujwala ZM: **Characterizing Extravascular Fluid Transport of Macromolecules in the Tumor Interstitium by Magnetic Resonance Imaging.** *Cancer Research* 2005, **65(4)**:1425.
- Dafni H, Gilead A, Nevo N, Eilam R, Harmelin A, Neeman M: **Modulation of the pharmacokinetics of macromolecular contrast material by avidin chase: MRI, optical, and inductively coupled plasma mass spectrometry tracking of triply labeled albumin.** *Magn Reson Med* 2003, **50(5)**:904-914.
- Schmidt-Ullrich R, Memet S, Lilienbaum A, Feuillard J, Raphael M, Israel A: **NF-kappaB activity in transgenic mice: developmental regulation and tissue specificity.** *Development* 1996, **122(7)**:2117-2128.
- Cheng J, Huang H, Pak J, Shapiro E, Sun TT, Cordon-Cardo C, Waldman FM, Wu XR: **Allelic loss of p53 gene is associated with genesis and maintenance, but not invasion, of mouse carcinoma in situ of the bladder.** *Cancer Res* 2003, **63(1)**:179-185.
- Garcia-Espana A, Salazar E, Sun TT, Wu XR, Pellicer A: **Differential expression of cell cycle regulators in phenotypic variants of transgenically induced bladder tumors: implications for tumor behavior.** *Cancer Res* 2005, **65(4)**:1150-1157.
- Van der Auwera I, Cao Y, Tille JC, Pepper MS, Jackson DG, Fox SB, Harris AL, Dirix LY, Vermeulen PB: **First international consensus on the methodology of lymphangiogenesis quantification in solid human tumours.** *Br J Cancer* 2006, **95(12)**:1611-1625.
- MicroBrightField, Inc** [<http://www.mbfioscience.com/>]
- Bernard R: **Hypothesis testing for correlation coefficients.** Boston: PVV Publishers; 1990.
- Saban R, Simpson C, Davis CA, Dozmorov I, Maier J, Fowler B, Ihnat MA, Hurst RE, Wershil BK, Saban MR: **Transcription factor network downstream of protease activated receptors (PARs) modulating mouse bladder inflammation.** *BCM Immunology* 2007, **8**:17.
- Nikon** [<http://www.nikoninstruments.com/>]
- Roper Scientific** [<http://www.roperscientific.com/>]
- NIS-Elements** [<http://www.nis-elements.com/>]
- Troy T, Jekic-McMullen D, Sambucetti L, Rice B: **Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models.** *Mol Imaging* 2004, **3(1)**:9-23.
- Microsoft** [<http://www.microsoft.com/>]
- Dafni H, Landsman L, Schechter B, Kohen F, Neeman M: **MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper-permeability and lymphatic uptake, followed by rapid inactivation of the growth factor.** *NMR Biomed* 2002, **15(2)**:120-131.
- Nanocs** [<http://www.nanocs.com/dextran.htm>]
- Coleman N, Stanley MA: **Expression of the myelomonocytic antigens CD36 and LI by keratinocytes in squamous intraepithelial lesions of the cervix.** *Hum Pathol* 1994, **25(1)**:73-79.
- Schluter C, Duchrow M, Wohlenberg C, Becker MH, Key G, Flad HD, Gerdes J: **The cell proliferation-associated antigen of antibody Ki-67: a very large, ubiquitous nuclear protein with numer-**

- ous repeated elements, representing a new kind of cell cycle-maintaining proteins. *J Cell Biol* 1993, **123**(3):513-522.
33. Limas C, Bigler A, Bair R, Bernhart P, Reddy P: **Proliferative activity of urothelial neoplasms: comparison of BrdU incorporation, Ki67 expression, and nucleolar organiser regions.** *J Clin Pathol* 1993, **46**(2):159-165.
 34. [<http://www.omrf.org/OMRF/Core/SmallAnimalMRI.asp>].
 35. Marchetti C, Poggi P, Farina A, Gritti A, Scelsi L, Scelsi R: **Structure of the initial lymphatics of the human urinary bladder with invasive urothelial tumors.** *Lymphology* 1996, **29**(3):118-125.
 36. Scelsi R, Scelsi L, Gritti A, Gozo M, Reguzzoni M, Marchetti C: **Structure of the lymphatic microcirculation in the human urinary bladder with different intraluminal pressure and distension.** *Lymphology* 1996, **29**(2):60-66.
 37. Miyata Y, Kanda S, Ohba K, Nomata K, Eguchi J, Hayashida Y, Kanetake H: **Tumor lymphangiogenesis in transitional cell carcinoma of the upper urinary tract: association with clinicopathological features and prognosis.** *J Urol* 2006, **176**(1):348-353.
 38. Schoppmann SF: **Lymphangiogenesis, inflammation and metastasis.** *Anticancer Res* 2005, **25**(6C):4503-4511.
 39. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K: **A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases.** *Embo J* 1996, **15**(2):290-298.
 40. Jeltsch M, Kaipainen A, Joukov V, Meng X, Lakso M, Rauvala H, Swartz M, Fukumura D, Jain RK, Alitalo K: **Hyperplasia of lymphatic vessels in VEGF-C transgenic mice.** *Science* 1997, **276**(5317):1423-1425.
 41. Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA: **Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4).** *Proc Natl Acad Sci USA* 1998, **95**(2):548-553.
 42. Lymboussaki A, Achen MG, Stacker SA, Alitalo K: **Growth factors regulating lymphatic vessels.** *Curr Top Microbiol Immunol* 2000, **251**:75-82.
 43. Helotera H, Alitalo K: **The VEGF family, the inside story.** *Cell* 2007, **130**(4):591-592.
 44. Saaristo A, Veikkola T, Tammela T, Enholm B, Karkkainen MJ, Pajusola K, Bueler H, Yla-Herttuala S, Alitalo K: **Lymphangiogenic gene therapy with minimal blood vascular side effects.** *J Exp Med* 2002, **196**(6):719-730.
 45. Karkkainen MJ, Ferrell RE, Lawrence EC, Kimak MA, Levinson KL, McTigue MA, Alitalo K, Finegold DN: **Missense mutations interfere with VEGFR-3 signalling in primary lymphoedema.** *Nat Genet* 2000, **25**(2):153-159.
 46. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, Demory A, Falkowska-Hansen B, Kurzen H, Ugurel S, Geginat G, Arnold B, Goerdts S: **Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1+, F4/80+, CD11b+ macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis.** *J Pathol* 2006, **209**(1):67-77.
 47. Schoppmann SF, Birner P, Stockl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D: **Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis.** *Am J Pathol* 2002, **161**(3):947-956.
 48. Skobe M, Hamberg LM, Hawighorst T, Schirner M, Wolf GL, Alitalo K, Detmar M: **Concurrent induction of lymphangiogenesis, angiogenesis, and macrophage recruitment by vascular endothelial growth factor-C in melanoma.** *Am J Pathol* 2001, **159**(3):893-903.
 49. Maruyama K, li M, Cursiefen C, Jackson DG, Keino H, Tomita M, Van Rooijen N, Takenaka H, D'Amore PA, Stein-Streilein J, Losordo DW, Streilein JW: **Inflammation-induced lymphangiogenesis in the cornea arises from CD11b-positive macrophages.** *J Clin Invest* 2005, **115**(9):2363-2372.
 50. Schledzewski K, Falkowski M, Moldenhauer G, Metharom P, Kzhyshkowska J, Ganss R, Demory A, Falkowska-Hansen B, Kurzen H, Ugurel S, Geginat G, Arnold B, Goerdts S: **Lymphatic endothelium-specific hyaluronan receptor LYVE-1 is expressed by stabilin-1(+), F4/80(+), CD11b(+)** macrophages in malignant tumours and wound healing tissue in vivo and in bone marrow cultures in vitro: implications for the assessment of lymphangiogenesis. *J Pathol* 2006.
 51. Kerjaschki D: **The crucial role of macrophages in lymphangiogenesis.** *J Clin Invest* 2005, **115**(9):2316-2319.
 52. Kerjaschki D, Huttary N, Raab I, Regele H, Bojarski-Nagy K, Bartel G, Krober SM, Greinix H, Rosenmaier A, Karlhofer F, Wick N, Mazal PR: **Lymphatic endothelial progenitor cells contribute to de novo lymphangiogenesis in human renal transplants.** *Nat Med* 2006, **12**(2):230-234.
 53. Renyi-Vamos F, Tovari J, Fillinger J, Timar J, Paku S, Kenessey I, Ostoros G, Agocs L, Soltesz I, Dome B: **Lymphangiogenesis correlates with lymph node metastasis, prognosis, and angiogenic phenotype in human non-small cell lung cancer.** *Clin Cancer Res* 2005, **11**(20):7344-7353.
 54. Van der Auwera I, Van den Eynden GG, Colpaert CG, Van Laere SJ, van Dam P, Van Marck EA, Dirix LY, Vermeulen PB: **Tumor lymphangiogenesis in inflammatory breast carcinoma: a histomorphometric study.** *Clin Cancer Res* 2005, **11**(21):7637-7642.
 55. Zeng Y, Opekin K, Horvath LG, Sutherland RL, Williams ED: **Lymphatic vessel density and lymph node metastasis in prostate cancer.** *Prostate* 2005, **65**(3):222-230.
 56. Stacker SA, Achen MG, Jussila L, Baldwin ME, Alitalo K: **Lymphangiogenesis and cancer metastasis.** *Nat Rev Cancer* 2002, **2**(8):573-583.
 57. Oliver G: **Lymphatic vasculature development.** *Nat Rev Immunol* 2004, **4**(1):35-45.
 58. Padera TP, Kadambi A, di Tomaso E, Carreira CM, Brown EB, Boucher Y, Choi NC, Mathisen D, Wain J, Mark EJ, Munn LL, Jain RK: **Lymphatic metastasis in the absence of functional intratumor lymphatics.** *Science* 2002, **296**(5574):1883-1886.
 59. Neeman M, Gilad AA, Dafni H, Cohen B: **Molecular imaging of angiogenesis.** *J Magn Reson Imaging* 2007, **25**(1):1-12.
 60. Pan D, Suzuki Y, Yang PC, Rockson SG: **Indirect magnetic resonance lymphangiography to assess lymphatic function in experimental murine lymphedema.** *Lymphatic research and biology* 2006, **4**(4):211-216.
 61. Kajiya K, Hirakawa S, Detmar M: **Vascular endothelial growth factor-A mediates ultraviolet B-induced impairment of lymphatic vessel function.** *The American journal of pathology* 2006, **169**(4):1496-1503.
 62. Lohrmann C, Foeldi E, Bartholoma JP, Langer M: **Magnetic resonance imaging of lymphatic vessels without image subtraction: a practicable imaging method for routine clinical practice?** *Journal of computer assisted tomography* 2007, **31**(2):303-308.
 63. Barrett T, Choyke PL, Kobayashi H: **Imaging of the lymphatic system: new horizons.** *Contrast media & molecular imaging* 2006, **1**(6):230-245.
 64. Bellin MF, Roy C: **Magnetic resonance lymphography.** *Current opinion in urology* 2007, **17**(1):65-69.
 65. Ferrusi I, Zhao J, van Helden D, von der Weid PY: **Cyclopiazonic acid decreases spontaneous transient depolarizations in guinea pig mesenteric lymphatic vessels in endothelium-dependent and -independent manners.** *Am J Physiol Heart Circ Physiol* 2004, **286**(6):H2287-2295.
 66. McCloskey KD, Hollywood MA, Thornbury KD, Ward SM, McHale NG: **Kit-like immunopositive cells in sheep mesenteric lymphatic vessels.** *Cell Tissue Res* 2002, **310**(1):77-84.
 67. **Abcam** [<http://www.abcam.com>]
 68. **Santa Cruz** [<http://www.scbt.com>]
 69. **Lab Vision** [<http://www.labvision.com>]

Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1471-2407/7/219/prepub>